Relay Therapeutics (RLAY) Operating Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Operating Expenses data on file, last reported at $81.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $81.6 million, down 11.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.1 million (down 18.02% YoY), and the FY2025 annual result was $318.1 million, down 16.83% from the prior year.
• Operating Expenses rose to $81.6 million in Q1 2026 per RLAY's latest filing, from $67.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $106.2 million in Q2 2023 and troughed at $63.1 million in Q1 2022.
• A 5-year average of $87.1 million and a median of $86.2 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 59.79% in 2022, then jumped 60.6% in 2023.
• A 5-year view of Operating Expenses shows it stood at $73.1 million in 2022, then gained by 26.11% to $92.2 million in 2023, then decreased by 7.83% to $85.0 million in 2024, then slipped by 20.42% to $67.6 million in 2025, then grew by 20.64% to $81.6 million in 2026.
• Business Quant data shows RLAY's Operating Expenses at $81.6 million in Q1 2026, $67.6 million in Q4 2025, and $80.4 million in Q3 2025.